Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety, Tolerability, and Proof-of-Concept Efficacy of Lisinopril in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS).

Trial Profile

Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety, Tolerability, and Proof-of-Concept Efficacy of Lisinopril in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS).

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2014

At a glance

  • Drugs Lisinopril (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 08 Sep 2014 Transparency Life Sciences has been awarded a Small Business Innovation Research grant to conduct this trial.
    • 30 Dec 2012 The IND for this trial has been approved according to a Transparency Life Sciences media release. The trial protocol has been uploaded onto the company website.
    • 07 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top